Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 6Not yet recruiting 3Completed 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 438Carboplatin 322Nivolumab 286Cyclophosphamide 280Specimen Handling 257Cisplatin 252Paclitaxel 249Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 167atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 113Oxaliplatin 112Etoposide 111Radiosurgery 109venetoclax 108Fluorouracil 108fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × axatilimab × Clear all
NCT05723055 2026-05-08

NAHL

University of Utah

Phase 2 Active not recruiting
9 enrolled
Lymphoid

Hodgkin Disease

NCT04710576 2026-03-16

AGAVE-201

Syndax Pharmaceuticals

Phase 2 Active not recruiting
241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡